REG - Tristel PLC - Market leadership in UK ENT market <Origin Href="QuoteRef">TSTL.L</Origin>

TristelAnnouncement

29/10/2014 13:43

RNS Number : 4428P
Tristel PLC
19 August 2014
TRISTEL plc
("Tristel", "Group" or the "Company")
Market leadership in UK Ear, Nose and Throat ("ENT") market
Tristel plc (AIM: TSTL), the manufacturer of infection prevention, contamination control and hygiene products, announces the publication in the British Journal of Nursing of an article titled "Decontamination methods for flexible nasal endoscopes."
The authors, based at Gloucestershire Royal Hospital, Gloucester and Great Western Hospital, Swindon, conducted a national survey of current practice in the United Kingdom for the decontamination of flexible nasal endoscopes. Two hundred out-patient ENT departments were interviewed and the total number of respondents was 121, representing approximately one-fifth of the public and private hospital market. Of the respondents, 72 hospitals (60%) used the Tristel Wipes System and 13 hospitals (11%) used a Tristel liquid disinfectant. Tristel believes the outcome of the survey is representative of the entire UK hospital market.
The survey confirms that Tristel products, in particular the Tristel Wipes System, are the most commonly used decontamination method for nasal endoscopes in the UK ENT market.
The Company expects to report global sales of the Tristel Wipes System during the year ended 30 June 2014 of 6m, of which 3.8m in the UK. Other hospital departments in which this Tristel product is widely used include ultrasound and cardiology. 
Paul Swinney, Chief Executive Officer, comments: "It has taken us a decade to establish this market leadership position in ENT. One of the great benefits of the Wipes System to a hospital is that it requires no capital investment and has no on-going maintenance cost. For a cash-strapped health system this is a tremendous advantage over the alternatives. As our three-part process is both unique and patented we have created a deeply entrenched position in this major clinical area."
Tristel plc
www.tristel.com
Paul Swinney, Chief Executive
Tel: 01638 721 500
Liz Dixon, Finance Director
finnCap
Geoff Nash / Charlotte Stranner, Corporate Finance
Tel: 020 7220 0500
Simon Starr, Corporate Broking
Walbrook PR Ltd
Tel: 020 7933 8780 or tristel@walbrookpr.com
Paul McManus
Mob: 07980 541 893
Lianne Cawthorne
Mob: 07854 391 303
 

This information is provided by RNS
The company news service from the London Stock Exchange
  END
MSCEVLFFZVFEBBV